Senti Biosciences Holdings, Inc. · NASDAQ:SNTI
Senti Biosciences — Corporate Update (December 2025)
34 slides from Senti Biosciences's corporate update, Dec 9, 2025
Slide 1: SENTI-202-101 Promising Results in R/R AML in Ongoing Phase 1 Trial
NASDAQ: SNTI | sentibio.com SENTI-202-101 Promising Results in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in Ongoing Phase 1 Trial (SENTI-202-101) December 9, 2025 Conference Call and Webcast
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securities Litigation Reform Act of 1995. Statements we make in this presentation may include statements which are not historical facts an
Slide 3: Presenters
3 Tim Lu, MD, PhD CEO and Co-Founder Kanya Rajangam, MD, PhD President, Head of R&D and CMO Nosha Farhadfar, MD Hematologist and Bone Marrow Transplant Physician
Slide 4: Tim Lu, MD, PhD, CEO and Co-Founder
Tim Lu, MD, PhD CEO and Co-Founder 4
Slide 5: Pipeline of Best-in-Class Logic Gated Cell Therapies
Pipeline of Best-in-Class Logic Gated Cell Therapies 5 Enable CAR-NK / CAR-T Cells to Address Blockbuster Liquid and Solid Tumors *ADC: antibody drug conjugate; TCE: T cell engagers Healthy CellsCancer Cells KILLKILL Recognize Single Antigen Target Single Antigen Target may be found on both cancer a
Slide 6: SENTI-202 Investment Highlights
First-in-Class Off-the-Shelf Logic-Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy Investment from Leading Healthcare Institutional Investors Lead Program SENTI-202 Investment Highlights 6 *CR: Complete Remission; CRh: CR with partial hematologic recovery; cCR: composite Complete Remission
Slide 7: SENTI-202 is a First-in-Class Off-the-Shelf Logic Gated CAR NK Cell Therapy
SENTI-202 is a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy for Blood Cancers 7 LSC: Leukemic stem cells; HSC: hematopoietic stem cell; HSPC: hematopoietic stem and progenitor cell Bivalent CD33 and/or FLT3 activating CAR Calibrated release IL-15 Endom
Slide 8: SENTI-202 is an Off-the-Shelf Allogeneic CAR-NK Cell Therapy Available On-Demand
SENTI-202 is an Off-the-Shelf Allogeneic CAR-NK Cell Therapy Available On-Demand 8 Lenti virus Outpatient use potential Isolate From Selected Donors Thaw and Infuse Scalable ~14 Day Manufacturing Process NK Cells Selected Donors Engineer CryopreserveExpand SENTI-202 Single transduction step delivers
Slide 9: SENTI-202 Has Potential to Address Major Unmet Needs in AML
9 NDAML estimates per Wall Street research; R/R AML estimates assume 60% of new AML cases become relapsed/refractory ~12K ~21K ~16K ~26K 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 50,000 R/R AML NDAML US EU ~28k ~47k Relapsed/Refractory AML Newly Diagnosed AML SENTI-202 Has the
Slide 10: Nosha Farhadfar, MD, Hematologist and Bone Marrow Transplant Physician
Nosha Farhadfar, MD Hematologist and Bone Marrow Transplant Physician 10
Slide 11: High Unmet Need in Patients with R/R AML
High Unmet Need in Patients with R/R AML Even With Recently Approved Therapies HCT: Hematopoietic cell transplantation; CR: complete remission; CRh: complete remission with partial hematologic recovery; OS: overall survival 1: Dohner Blood 2022; 2: USPI Idhifa, Rezlidhia, Xospata, Tibsovo, Revuforj,
Slide 12: AML Response Categories and Clinical Benefit
AML Response Categories and Clinical Benefit Peripheral Blood CountsAML Blasts ANC ≥ 1.0 x 109/L and PLT ≥ 100 x 109/L Bone marrow blasts <5% and Absence of circulating blasts and Absence of extramedullary disease When assessed for measurable residual disease or MRD (e.g., by MFC, sensitivity of ≤10
Slide 13: How SENTI-202 Could Fit Into the Evolving AML Treatment Landscape
How SENTI-202 Could Fit Into the Evolving AML Treatment Landscape 13 • Targets LSCs while sparing healthy HSPCs • Potential to deliver deep, durable MRD- responses • Potential to be stand-alone therapy in patients not eligible for HCT • Safety profile allows use before or after targeted therapies
Slide 14: Kanya Rajangam, MD, PhD, President, Head of R&D and CMO
Kanya Rajangam, MD, PhD President, Head of R&D and CMO 14
Slide 15: SENTI-202-101 Phase 1 Trial Design
2 DOSE LEVELS and 2 SCHEDULES Starting dose level anticipated to be biologically active SENTI-202-101 is a Multicenter, Multinational, Open-label Phase 1 Trial in Patients with R/R Hematologic Malignancies* Key Eligibility Criteria Key Objectives Primary objective • Safety and determination of MTD/R
Slide 16: Study Treatment Dosing and SENTI-202 RP2D Selection
1 R P 2D Study Treatment Dosing and SENTI-202 RP2D Selection 21Dose Level 1.5 × 1091 × 109CAR+ NK Cells/Dose Here we present clinical data from 20 R/R AML patients, including 14 at RP2D and 6 at Dose Level 1 9 R/R AML patients (pts) initially enrolled in dose finding 6 pts in Dose Level 1 (3 each in
Slide 17: Patients with Multiple Baseline Adverse-risk Characteristics
Study Enrolled R/R AML Patients with Multiple Baseline Adverse-risk Characteristics and Poor Prognosis Dose Level 2/RP2DDose Level 1 All Patients N=20 1.5 x 109 CAR+ NK cells/ dose N=14 1 x 109 CAR+ NK cells/ dose N=6 Baseline Characteristics 49 (19, 72)49 (19, 69)52.5 (26, 72)Age, yr, median (range
Slide 18: Heavily Pretreated R/R AML Population
Heavily Pretreated R/R AML Population Including Many Primary Refractory & Refractory to Most Recent Line of Therapy Before Study Entry Dose Level 2/ RP2DDose Level 1 All Patients N=20 1.5 x 109 CAR+ NK cells/ dose N=14 1 x 109 CAR+ NK cells/ dose N=6 Prior AML Treatments 0.75 (0.2, 8.6)0.85 (0.2, 8.
Slide 19: Treatment Exposure and No Discontinuations Due to Adverse Events
Patients Received a Median of 1 Cycle on Treatment Overall and None Discontinued Due to an Adverse Event Dose Level 2/ RP2DDose Level 1 All Patients N=20 1.5 x 109 CAR+ NK cells/ dose N=14 1 x 109 CAR+ NK cells/ dose N=6 Exposure Number of SENTI-202 treatment cycles, n (%) 14 (70)12 (86)2 (33)1 Cycl
Slide 20: Grade 3+ Treatment Emergent Adverse Events and SAEs
Any Grade 3+ Treatment Emergent Adverse Events (AE) or Serious Adverse Events (SAE) On Study, Regardless of Relationship to SENTI-202 Dose Level 2/ RP2DDose Level 1 All Patients N=20 1.5 x 109 CAR+ NK cells/ dose N=14 1 x 109 CAR+ NK cells/ dose N=6 Event Term 18 (90)12 (86)6 (100) Any ≥ Grade 3 AE,
Slide 21: SENTI-202 Related AEIs Predominantly Grade 1/2 Pyrexia
SENTI-202 Related AEIs are Predominantly Grade 1/2 Pyrexia Events That are Readily Managed with Standard of Care Serious? / Resolution AEI Term Duration of Event Onset Day from Most Recent Dose of SENTI- 202 Grade Event Term PtDose N o / Re so lv ed w ith S ta nd ar d of C ar e CRS <24 hours0 2 1 Py
Slide 22: 50% of Patients Achieved a Response with SENTI-202
50% of Patients Achieved a Response with SENTI-202 Treatment Dose Level 2/RP2DDose Level 1 All Patients N=18^ 1.5 x 109 CAR+ NK cells/ dose N=12 1 x 109 CAR+ NK cells/ dose N=6 Response 9 (50)6 (50)3 (50)Overall Response Rate (ORR), n (%) 7 (39)5 (42)2 (33)CR/CRh rate, n (%) Response Category, n(%)
Slide 23: SENTI-202 Responses Are Durable
SENTI-202 Responses Are Durable With Longest Durability > 1 Year C1 C2 C1 C2 C1 C2 C1 C1 C1 C1 C1 C1 C1 C2 C1 C2 C1 C2 C1 C1 C1 C1 C1 C1 Post HCT visceral GvHD Tx Tx Tx Tx Tx C1/C2 Cycle 1/2 start EOT End of study treatment Ongoing as of data cut Tx HCT Withdrawal of consent Death Treatment and Foll
Slide 24: Selective AML Blast and Leukemic Stem Cell Killing
Selective AML Blast and Leukemic Stem Cell (LSC) Killing Consistent with SENTI-202 CD33/ FLT3 “OR” Logic Gate Mechanism of Action 24 AML blast reduction on study* 0 20 40 60 80 100 To ta l B on e M ar ro w B la st s (% ) Baseline Best Response LSC reduction on study in Responders (ORR)# * Patient 12
Slide 25: Selective Protection of Healthy Hematopoietic Stem & Progenitor Cells
Selective Protection of Healthy Hematopoietic Stem & Progenitor Cells (HSPC) Consistent with SENTI-202 “NOT” Logic Gate Mechanism of Action 25 HSPC in Responders (ORR) at baseline 100 1 0.1 0 % H SP C o f a ll ce lls CR/CRh MLFS 10 • Among all responders (ORR), patients with any detectable HSPC at b
Slide 26: Rapid Peripheral Blood Cell Count Recovery
Rapid Peripheral Blood Cell Count Recovery Consistent with SENTI-202’s Unique NOT Gate Mechanism of Action Data from an open clinical database of an ongoing study as of 17-Oct-2025; Cycles 1 & 2 represented in plot for patients receiving 2 cycles of SENTI-202; CR: complete remission; CRh: CR with pa
Slide 27: SENTI-202 Peripheral Blood Exposure
SENTI-202 Peripheral Blood Exposure is Generally Consistent Across All Dosed Patients • SENTI-202 is detected in periphery of treated subjects, with PK profile consistent with allogeneic NK cell therapies • Peripheral expansion in the first 14 days • Clearance from periphery after the first two week
Slide 28: SENTI-202 Demonstrated Promising Results in R/R AML
SENTI-202 Demonstrated Promising Results in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia • SENTI-202-101 trial has enrolled heavily treated R/R AML patients with poor prognosis • Dose finding is complete with no DLTs/ MTD and RP2D confirmed • Dose expansion is ongoing at RP2D of 1.5 x
Slide 29: Next Steps to Accelerate SENTI-202 into Pivotal Study
29 Next Steps to Accelerate SENTI-202 into Pivotal Study *Assumes additional financing to continue pivotal process development end of 2025 and to support enrolment of dose expansion patients in 2026 20262025Product SENTI-202 Clinical Trial* SENTI-202 CMC Process 20 patients dosed, RP2D confirmed RMA
Slide 30: Tim Lu, MD, PhD, CEO and Co-Founder
Tim Lu, MD, PhD CEO and Co-Founder 30
Slide 31: SENTI-202 Summary
First-in-Class Off-the-Shelf Logic-Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy Investment from Leading Healthcare Institutional Investors Lead Program SENTI-202 SENTI-202 Summary 31 *CR: Complete Remission; CRh: CR with partial hematologic recovery; cCR: composite Complete Remission; M
Slide 32: Programming Gene Circuits to Enhance Cell and Gene Therapies
Programming Gene Circuits to Enhance the Potential of Cell and Gene Therapies SENTI BIO CONFIDENTIAL, #CT014 32 Multi-Arming to address Immunosuppressive Tumor Microenvironments Regulator Dial to enable Control for Safety Smart Sensor to enable Specificity for Disease Logic Gating to address Antigen
Slide 33: Gene Circuits Across Diverse Cell and Gene Therapy Modalities
Senti’s Gene Circuits can be Used Across Diverse Cell and Gene Therapy Modalities iPSCs In vivo cell therapy AAVs & other gene therapy modalities T cells NK cells Gene Circuit Multi-Arming Regulator Dial Smart Sensor Logic Gating Technology 33
Slide 34: 34
34